Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
PROMIT is a single arm phase 2 trial evaluating the clinical activity of immune checkpoint
blockade (ICB) after administration of dacarbazine (DTIC) in patients with unresectable or
metastatic, BRAF wildtype melanoma with primary resistance to anti-programmed-cell-death-1
(PD-1/PD-L1) or PD-1 plus anti-cytotoxic-T-lymphocyte antigen 4 (CTLA-4) blockade therapy. If
the activity is clinically meaningful, DTIC could become a new therapeutic option to break
primary resistance to immunotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Collaborators:
University Hospital Regensburg Wuerzburg University Hospital